Patents by Inventor Peter Kresten Nielsen
Peter Kresten Nielsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9963496Abstract: The invention relates to derivatives of glucagon analogs comprising the substitutions Imp1 and His3, a substituent having three to ten negatively charged moieties covalently attached to a side chain of a lysine as well as intermediates and compositions thereof and their use in medicine.Type: GrantFiled: February 18, 2015Date of Patent: May 8, 2018Assignee: Novo Nordisk A/SInventors: Jesper F. Lau, Thomas Kruse, Peter Kresten Nielsen
-
Patent number: 9655974Abstract: Analogs of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD).Type: GrantFiled: July 18, 2011Date of Patent: May 23, 2017Assignee: Novo Nordisk A/SInventors: Tina Moeller Tagmose, Patrick William Garibay, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Kristian Sass Bak-Jensen, Helle Fabricius Woeldike
-
Publication number: 20170008943Abstract: The invention relates to derivatives of glucagon analogues comprising the substitutions Imp1 and His3, a substituent having three to ten negatively charged moieties covalently attached to a side chain of a lysine as well as intermediates and compositions thereof and their use in medicine.Type: ApplicationFiled: February 18, 2015Publication date: January 12, 2017Applicants: Novo Nordisk A/S, Novo Nordisk A/SInventors: Jesper F. Lau, Thomas Kruse, Peter Kresten Nielsen
-
Publication number: 20160347812Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: ApplicationFiled: August 16, 2016Publication date: December 1, 2016Inventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Ulrich Sensfuss, Peter Kresten Nielsen
-
Patent number: 9486505Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: GrantFiled: July 9, 2013Date of Patent: November 8, 2016Assignee: Novo Nordisk A/SInventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Ulrich Sensfuss, Peter Kresten Nielsen
-
Patent number: 9486506Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: GrantFiled: February 24, 2015Date of Patent: November 8, 2016Assignee: Novo Nordisk A/SInventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Ulrich Sensfuss, Peter Kresten Nielsen
-
Patent number: 9260502Abstract: The present invention relates to novel insulin analogs comprising mutations at position A14 in the A chain and at positions B27, B28, B29 and B30 in the B chain and exhibiting resistance towards protease; a method for the preparation of such insulin analogs; insulin preparations containing the insulin analogs of the invention; and, a method of treating diabetes mellitus using these insulin analogs.Type: GrantFiled: March 13, 2009Date of Patent: February 16, 2016Assignee: Novo Nordisk A/SInventors: Peter Kresten Nielsen, Frantisek Hubalek, Inger Lautrup-Larsen, Per Balschmidt, Svend Ludvigsen, Thomas Børglum Kjeldsen
-
Publication number: 20150182594Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: ApplicationFiled: February 24, 2015Publication date: July 2, 2015Inventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Ulrich Sensfuss, Peter Kresten Nielsen
-
Patent number: 9018161Abstract: The present invention relates to novel insulin analogues exhibiting resistance towards protease, wherein at least two amino acids are substituted and/or deleted relative to the parent insulin molecule. A method for the preparation of such insulin analogues, insulin preparations containing the insulin analogues of the invention and a method of treating diabetes mellitus using these insulin analogues is also provided.Type: GrantFiled: September 20, 2007Date of Patent: April 28, 2015Assignee: Novo Nordisk A/SInventors: Peter Kresten Nielsen, Frantisek Hubalek, Inger Lautrup-Larsen, Svend Ludvigsen, Ulla Ribel-Madsen, Per Balschmidt, Per Nørgaard, Svend Havelund
-
Publication number: 20130288958Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: ApplicationFiled: July 9, 2013Publication date: October 31, 2013Inventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Ulrich Sensfuss, Peter Kresten Nielsen
-
Publication number: 20130252884Abstract: Novel analogues of Fibroblast Growth Factor 21 (FGF21), derivatives thereof having a modifying moiety covalently attached thereto, and pharmaceutical use of these analogues and derivatives, in particular, for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD) are described.Type: ApplicationFiled: June 6, 2011Publication date: September 26, 2013Applicant: NOVO NORDISK A/SInventors: Patrick William Garibay, Helle Woeldike, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Birgitte Andersen, Jishu Wang, Kristian Sass Bak-Jensen, Tina Moeller Tagmose
-
Patent number: 8541368Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: GrantFiled: September 21, 2012Date of Patent: September 24, 2013Assignee: Novo Nordisk A/SInventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Ulrich Sensfuss, Peter Kresten Nielsen
-
Publication number: 20130190232Abstract: Analogues of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD).Type: ApplicationFiled: July 18, 2011Publication date: July 25, 2013Applicant: NOVO NORDISK A/SInventors: Tina Moeller Tagmose, Patrick William Garibay, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Birgitte Andersen, Jishu Wang, Kristian Sass Bak-Jensen, Helle Fabricius Woeldike
-
Publication number: 20120035099Abstract: Derivatives of Fibroblast Growth Factor 21 which have improved properties for treating diabetes can be prepared by a recombinant process.Type: ApplicationFiled: June 6, 2011Publication date: February 9, 2012Applicant: NOVO NORDISK A/SInventors: WILLIAM PATRICK GARIBAY, HELLE WÖLDIKE, XUJIA ZHANG, HENNING THØGERSEN, PETER KRESTEN NIELSEN, BIRGITTE ANDERSEN, JISHU WANG, KRISTIAN SASS BAK-JENSEN, TINA MØLLER TAGMOSE
-
Publication number: 20110092419Abstract: The present invention relates to novel insulin analogues comprising mutations at position A14 in the A chain and at positions B27, B28, B29 and B30 in the B chain and exhibiting resistance towards protease; a method for the preparation of such insulin analogues; insulin preparations containing the insulin analogues of the invention; and, a method of treating diabetes mellitus using these insulin analogues.Type: ApplicationFiled: March 19, 2009Publication date: April 21, 2011Applicant: Novo Nordisk A/SInventors: Peter Kresten Nielsen, Frantisek Hubalek, Inger Lautrup-Larsen, Per Balschmidt, Svend Ludvigsen, Thomas Børglum Kjeldsen
-
Publication number: 20100216715Abstract: The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability.Type: ApplicationFiled: January 22, 2010Publication date: August 26, 2010Applicant: Novo Nordisk A/SInventors: Tina Møller Tagmose, Patrick William Garibay, Bírgítte Andersen, Jishu Wang, Kílían Waldemar Conde-Frieboes, Kristían Sass Bak-Jensen, Henning Thøgersen, Helle Wöldike, Peter Kresten Nielsen, Rita Slaaby, Xujia Zhang, Birgit Wieczorek
-
Publication number: 20100009898Abstract: The present invention relates to novel insulin analogues exhibiting resistance towards protease, wherein at least two amino acids are substituted and/or deleted relative to the parent insulin molecule. A method for the preparation of such insulin analogues, insulin preparations containing the insulin analogues of the invention and a method of treating diabetes mellitus using these insulin analogues is also provided.Type: ApplicationFiled: September 20, 2007Publication date: January 14, 2010Inventors: Peter Kresten Nielsen, Frantisek Hubalek, Inger Lautrup-Larsen, Svend Ludvigsen, Ulla Ribel-Madsen, Per Balschmidt, Per Norgaard, Svend Havelund